Entrada Therapeutics, Inc. 8-K

What Happened

• On June 10, 2026, Entrada Therapeutics, Inc. (NASDAQ: TRDA) held its 2026 Annual Meeting of Stockholders in a virtual-only format and reported matters submitted to a vote. The company disclosed proposed amendments to its 2021 Stock Option and Incentive Plan and its 2021 Employee Stock Purchase Plan to modify the plans’ evergreen provisions.
• The amendments would add the company’s outstanding pre‑funded warrants to the count of shares of common stock considered “issued and outstanding” as of each December 31 used to calculate the annual automatic increase in shares available under each plan. Summaries were included in the company’s definitive proxy statement filed April 24, 2026; full amendments are attached as Exhibits 10.1 and 10.2 to the 8‑K.

Key Details

• Meeting date and format: June 10, 2026; virtual-only live webcast.
• Plans affected: Entrada Therapeutics 2021 Stock Option and Incentive Plan and 2021 Employee Stock Purchase Plan (ESPP).
• Amendment purpose: include outstanding pre‑funded warrants in the evergreen formula used to calculate annual share increases.
• Reference materials: Proxy statement filed April 24, 2026; full amendment texts attached as Exhibit 10.1 and Exhibit 10.2.

Why It Matters

• Evergreen provisions determine how many new shares can be added each year to equity compensation and purchase plans. Including pre‑funded warrants in the “issued and outstanding” share count can increase the baseline used for annual increases, which may expand the number of shares available for grants or purchases over time.
• For shareholders, that can affect future dilution from stock awards and ESPP issuance. Investors should watch subsequent disclosures (e.g., vote results, updated share counts, and future equity grants) to assess the practical impact on outstanding shares and dilution.